Spruce Street Capital »

Savara shares owned by Spruce Street Capital

Quarter-by-quarter ownership of Savara (SVRA) shares owned by Spruce Street Capital from 13F filings

Historical chart of Spruce Street Capital investment in Savara

Tip: Access up to 7 years of quarterly data

All positions including Savara held by Spruce Street Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Savara by Spruce Street Capital

Quarter filed Position value Share count Share price at filing
2026-06-30 $21M 3.5M 6.16

More positions owned by Spruce Street Capital

Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA)
Relay Therapeutics (RLAY)
Lb Pharmaceuticals Com Shs (LBRX)
Relmada Therapeutics (RLMD)
Alto Neuroscience Com Shs (ANRO)
Dianthus Therapeutics (DNTH)
Alkermes SHS (ALKS)
Savara (SVRA)
Vaxcyte (PCVX)
Enliven Therapeutics (ELVN)
Enanta Pharmaceuticals (ENTA)
Perspective Therapeutics Com New (CATX)
Inflarx Nv (IFRX)
Surrozen Com New (SRZN)
Alumis (ALMS)

View all positions for Spruce Street Capital

Top funds holding Savara

NEA Management Company
Bain Capital Life Sciences Investors
VR Adviser
Deerfield Management Company
TCG Crossover Management
BlackRock
Frazier Life Sciences Management
Polar Capital Holdings
Vanguard Capital Management
Nantahala Capital Management
State Street Corporation
Marshall Wace
Rtw Investments
Woodline Partners
Geode Capital Management

View all funds holding Savara